Nahdi Medical Company

The analyst consensus remains OUTPERFORM with an average price target of SAR 124.21, representing a significant 36.56% upside from the last close of SAR 90.95. Firms like Morgan Stanley maintain an Overweight rating and Citi retains a Buy, signaling confidence in Nahdi's long-term growth trajectory and undervalued positioning.

JP Morgan reduced its price target while maintaining a Neutral rating, and Riyad Capital downgraded Nahdi Medical to Neutral while trimming its price target following Q1 2026 earnings. These actions reflect concern that near-term headwinds may not justify current valuation levels, limiting meaningful upside.

Despite geopolitical headwinds, Morgan Stanley and Citi both trimmed price targets while retaining positive ratings in early 2026, suggesting that analysts with an optimistic view believe Nahdi's domestic Saudi healthcare market exposure provides enough resilience to weather regional geopolitical turbulence without derailing its core growth story.

United Securities cut Nahdi Medical's target price specifically citing increasing geopolitical risks in March 2026, reflecting concern that broader regional instability could weigh on consumer spending, supply chains, and the company's ability to execute its expansion strategy over the next 12 months.

Saudi Arabia's e-commerce market is projected to grow at an 11.92% CAGR, reaching USD 54.87 billion by 2031. As one of Saudi Arabia's leading pharmacy and healthcare retailers, Nahdi stands to benefit significantly from this digital tailwind by expanding its online sales channels and capturing a growing share of health-related e-commerce spending.

While the Saudi e-commerce market is expanding rapidly, Nahdi faces intensifying digital competition from both local and international players. The transition to digital retail requires sustained capital investment in technology and logistics, which could pressure margins and delay profitability improvements, raising questions about the return on digital transformation investments.